DITROPAN

Compare DITROPAN  to:
Compare
Compare

Generic Name for DITROPAN

Oxybutynin chloride 5mg; scored tabs.

Legal Classification:

Rx

Pharmacological Class for DITROPAN

Antispasmodic/anticholinergic.

Manufacturer of DITROPAN

Ortho-McNeil Pharmaceuticals, Inc.

Indications for DITROPAN

Symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (eg, urinary urgency, frequency, leakage, urge incontinence, dysuria).

Adult dose for DITROPAN

5mg 2–3 times a day; max 20mg/day.

Children's dosing for DITROPAN

<5yrs: not recommended. ≥5yrs: 5mg twice daily; max 15mg/day.

Also:

Contraindications for DITROPAN

Uncontrolled glaucoma. GI obstruction. Paralytic ileus. Intestinal atony in elderly or debilitated. Severe colitis. Myasthenia gravis. Megacolon. Toxic megacolon in ulcerative colitis. Obstructive uropathies. Unstable cardiovascular status in acute hemorrhage.

Precautions for DITROPAN

Activities requiring mental alertness. Diarrhea. Hepatic or renal disease. Autonomic neuropathy. Hyperthyroidism. Cardiovascular disease. Hiatal hernia. GI or GU obstruction. Ulcerative colitis. Exposure to extreme heat. Elderly. Pregnancy (Cat.B). Nursing mothers.

Interactions for DITROPAN

Potentiates drowsiness with alcohol, other CNS depressants. Additive anticholinergic effects with other anticholinergics. May be potentiated by CYP3A4 inhibitors. Decreases GI motility, possibly affecting absorption of other drugs.

Adverse Reactions for DITROPAN

Dry mouth, constipation, somnolence, headache, diarrhea, nausea, tachycardia, blurred vision, dry eyes, other anticholinergic effects.

How is DITROPAN supplied?

Tabs—100, 1000
Syrup—pt

Related Disease:

Overactive bladder

Related Resources

Phase 3 study of Anturol for the treatment of overactive bladder (OAB)

March 02, 2010

Antares Pharma announced that it has completed enrollment in the double-blind portion of their Phase 3 trial of Anturol (transdermal oxybutynin ATD gel) for the treatment of overactive bladder (OAB).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Gelnique gel available for overactive bladder (OAB)

May 21, 2009

Gelnique gel (oxybutynin chloride 10%) has been made available by Watson as a once-daily topical treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

Phase 3 results of Gelnique for female overactive bladder

April 28, 2009

Watson Pharmaceuticals announced results of its Phase 3 study of Gelnique (oxybutynin chloride) 10% gel for the treatment of women with overactive bladder (OAB) and urinary urge incontinence.

Gelnique gel approved for OAB

January 28, 2009

The FDA has approved Watson's Gelnique (oxybutynin chloride) gel 10% for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.